TB research and development funding perilously off track of UN commitments to end TB by 2030.

Treatment Action Group launches the 2023 Tuberculosis Diagnostics Pipeline Report.

This new resource lays out what activists need to know about the new drug-resistant TB treatment regimens, and equips them with actions they can take and arguments they can use to advocate for access to those regimens.

Historic price reductions will allow millions more people to receive TB prevention, treatment and testing.

Treatment Action Group launches the first TB chapter of its 2023 Pipeline Report.

The report portrays how GSK’s financial interests have – and will likely continue to – set back progress against the world’s deadliest infectious disease lays bare just how egregiously large pharmaceutical companies bilk the global public, and makes an urgent case for government and philanthropic funders to take action and demand better.

A sobering new analysis from Treatment Action Group shows that governments failed to meet previous commitments to fund TB research.

Ahead of the UN General Assembly High-Level Meeting on TB, the 1/4/6×24 Campaign is sounding the alarm that the political declaration commits neither the funding nor the actions needed to expand access to the best-available TB regimens and diagnostics.

Treatment Action Group releases an updated Information note providing details on the new 0.15% fair share funding targets for TB research.

Advocates call for clarity on the terms of the Johnson & Johnson's deal with the Stop TB Partnership’s Global Drug Facility to supply generic bedaquiline.